All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Nivolumab Plus Gemcitabine/Cisplatin Shows Favorable OS/PFS Trend in Asian Unresectable/Metastatic Urothelial Cancer Subpopulation

January 15th 2025

First-line nivolumab plus chemotherapy numerically improved survival vs chemotherapy alone in Asian patients with unresectable/metastatic urothelial cancer.

Neoadjuvant SHR-A1811 Produces pCRs in Early HER2+ Breast Cancer

January 15th 2025

Jun-Jie Li, MD, discusses the efficacy of neoadjuvant SHR-A1811, a HER2-directed antibody-drug conjugate, in HER2-positive breast cancer.

Durvalumab Shifts Decades-Long SOC as First FDA-Approved Immunotherapy Regimen in LS-SCLC

January 15th 2025

Suresh Senan, MRCP, FRCR, PhD, details how the FDA approval of durvalumab has changed care for patients with limited-stage small cell lung cancer.

Sasanlimab Plus BCG Could Alter Treatment Paradigm in BCG-Naive, High-Risk NMIBC

January 14th 2025

Neal Shore, MD, FACS, discusses implications of data for sasanlimab plus BCG in BCG-naive, high-risk non–muscle-invasive bladder cancer.

Cellular Therapies and Novel Targeted Agents Will Shape the Future of R/R ALL Management

January 14th 2025

Marlise Luskin, MD, MSCE, discusses the treatment paradigm for relapsed/refractory ALL and research seeking to integrate agents into the frontline setting

Emerging HER2-Directed Agents May Address Resistance to SOC Regimens in Pretreated HER2+ Breast Cancer

January 14th 2025

Ian Krop, MD, PhD, spotlights emerging HER2-directed agents of interest for pretreated patients with HER2-positive breast cancer.

Researchers Resolve Uncertainty in BRCA2 Testing, Improving Cancer Risk Assessment and Patient Care

January 14th 2025

Findings will help identify patients with breast, ovarian, pancreatic, or prostate cancer who may benefit from targeted therapies.

Continuous Synthetic Hypericin Generates Responses in Early-Stage Cutaneous T-Cell Lymphoma

January 14th 2025

Treatment with synthetic hypericin for up to 12 months produced responses in early-stage cutaneous T-cell lymphoma.

Savolitinib Earns Full Approval in China for Locally Advanced/Metastatic MET Exon 14+ NSCLC

January 14th 2025

Savolitinib has received full NMPA approval for locally advanced/metastatic non–small cell lung cancer with MET exon 14 skipping alterations.

Selecting Checkpoint Inhibitor–Based Regimens in Clear Cell RCC Requires Several Considerations

January 14th 2025

Yousef Zakharia, MD, discusses the evolving use of checkpoint inhibitors and emerging triplet regimens in clear cell renal cell carcinoma.

Genetic Testing Considerations and Questions Persist Surrounding Tumor-Agnostic Approvals

January 14th 2025

Pedro Barata, MD, details factors affecting treatment selection with biomarker-based approvals and highlights questions regarding genetic testing.

Adjuvant Nivolumab Plus Chemoradiotherapy Meets DFS End Point in Locally Advanced HNSCC

January 14th 2025

Adjuvant nivolumab plus chemoradiotherapy improved disease-free survival in resected, locally advanced head and neck squamous cell carcinoma.

Isatuximab Plus Pomalidomide and Dexamethasone Receives Approval in China for Relapsed/Refractory Multiple Myeloma

January 13th 2025

China’s NMPA has approved isatuximab plus pomalidomide and dexamethasone in adult patients with pretreated multiple myeloma.

FDA Approval of Subcutaneous Nivolumab Represents Paradigm Shift in Solid Tumor Management

January 13th 2025

Roxana S. Dronca, MD, discusses the FDA approval of subcutaneous nivolumab across solid tumor indications.

PDUFA Date Set for 3-Month Variation of Leuprolide Mesylate in Advanced Prostate Cancer

January 13th 2025

The FDA has set the PDUFA date for the 3-month, 21-mg variation of leuprolide mesylate in advanced prostate cancer for August 29, 2025.

Mount Sinai Researchers Uncover Why Some Leukemia Cells May Resist Treatment

January 13th 2025

Research from the Icahn School of Medicine at Mount Sinai provides new insights into acute myeloid leukemia (AML) and its resistance to a common treatment.

Dato-DXd Receives FDA Priority Review in Pretreated EGFR-Mutated NSCLC

January 13th 2025

The BLA for Dato-DXd in locally advanced or metastatic EGFR-mutated NSCLC has been accepted and granted priority review by the FDA.

Adjuvant Cemiplimab Improves DFS in High-Risk Cutaneous Squamous Cell Carcinoma

January 13th 2025

Adjuvant therapy with cemiplimab improved DFS vs placebo in patients with high-risk cutaneous squamous cell carcinoma after surgery.

Zanubrutinib Plus Obinutuzumab/Venetoclax Associated With Durable uMRD4 Outcomes in Treatment-Naive CLL

January 13th 2025

Patients with treatment-naive CLL who received the BOVen regimen had an increased likelihood of achieving uMRD levels in peripheral blood and bone marrow.

Neoadjuvant Niraparib Plus Dostarlimab Data Support Development of Non-Chemo Approaches in BRCA+, ER+ Breast Cancer

January 13th 2025

Erica L. Mayer, MD, MPH, responses with preoperative niraparib plus dostarlimab in patients with BRCA-mutant, ER-positive, HER2-negative breast cancer.